Clinically, a DC vaccine (ICT-107) loaded with six synthetically processed GBM-associated peptides, four of which (HER2, TRP-2, AIM-2, and IL13Rα2) are considered GSC-associated, has shown promising results in phase II trial for newly diagnosed GBM patients [70]. Here, IL13RA2 is linked to glioblastoma.